* Cangene Corp., of Toronto, signed a formal purchaseagreement with Apotex Biotechnology Holdings Inc. toacquire its subsidiary, Rh Pharmaceuticals Inc., ofWinnipeg, Manitoba. Apotex will own about 85 percentof the new company. (See BioWorld Today, Aug. 1,1995, p. 1.)
* Gilead Sciences Inc., of Foster City, Calif., said Vistidenow is available under a treatment investigational newdrug program for those with relapsing cytomegalovirusretinitis.
* LeukoSite Inc., of Cambridge, Mass., was awarded twosmall business innovation research grants. One is for aproject to develop new drugs for inflammatory boweldisease; the other for development of discoverytechnology based on the use of the micro-organismDictyostelium (slime mold).
(c) 1997 American Health Consultants. All rights reserved.